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1 These authors contributed equally to this work.MicroRNA proﬁling of diseased/non-diseased tissue has identiﬁed expression signatures associated
with a wide range of pathogenic conditions including malignancy. For example, colon cancer is asso-
ciated with the under expression of miRNA-143 yet the molecular etiology of under expression is
unknown. The K-Ras oncogene is a target of miRNA-143. Here, we show that the ecotropic viral inte-
gration site 1 oncoprotein (Evi1) is a transcriptional suppressor of the miRNA-143 gene. We ﬁnd an
indirect relationship between miRNA-143 and Evi1 expression. A complex molecular axis linking
Evi1, miRNA-143 is operational in human colon cancer.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNA are a relatively recently described class of non-cod-
ing RNA that impact gene expression by translational arrest or di-
rect degradation of mRNA depending upon the degree of homology
between the miRNA itself and the target RNA. Presently, the
human genome harbors at least 940 genes encoding miRNA
(Sanger miRBase, Release 15, April 2010) but this number is ex-
pected to increase with the newly gained power of deep sequenc-
ing technology. Numerous studies have been conducted to proﬁle
miRNA in healthy and diseased tissue with the majority of investi-
gations focusing on the process of malignancy. Indeed, a global
reduction in mature miRNA expression has been described in a
broad range of primary cancerous tissues, the exact etiology of
which is unclear [1]. MiRNA expression patterns have been impli-
cated in diverse processes in carcinogenesis from metastasis to
oncogene expression. For example, recent work has identiﬁed both
the p53 tumor suppressor and K-Ras as targets of miRNA [2–4].
Both proteins are known targets for at least two miRNA species
(p53: miRNA-125a/b and K-Ras: miRNA-let7a/143).chemical Societies. Published by E
ratnam).While much data has emerged on presumed miRNA targets, less
is known regarding the cellular cues that activate or repress a given
miRNA gene. Given that miRNA are potential druggable host fac-
tors, cellular proteins that impact their gene expression may serve
as additional targets for inhibition or stimulation. Furthermore, the
discovery of cellular cofactors impacting miRNA gene expression
may offer broader pathogenic insight into basic disease processes.
Here, we focus on human miRNA-143 that is under-expressed in
several human neoplasms including colon, ovarian, esophageal,
bladder and B-cell cancer [5,6]. Using cell lines and primary
cancerous/non-cancerous tissue, we show that miRNA-143 expres-
sion is directly controlled by the ecotropic viral integration site 1
oncogene (Evi1) that serves as a transcriptional suppressor of
the miRNA-143 gene. In cell lines and primary tumor tissue, we
describe an axis that inversely links Evi1 protein levels to
miRNA-143 expression and the latter’s oncogenic target: K-Ras.
2. Materials and methods
2.1. Constructs
MiRNA expression vectors were created by amplifying 300 nt
of pri-miRNA from human genomic DNA. Inclusion of appropriate
restriction enzyme sites in primers allowed their introduction into
pcDNA 3.1 (+) vector (Invitrogen). MiRNA-143 mutants werelsevier B.V. All rights reserved.
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(Stratagene). The mutagenesis reaction was performed in 50 lL to-
tal volume using 80 ng of template DNA according to the instruc-
tions of the manufacturer. All constructs were sequence veriﬁed.
Luciferase based reporter assays were created by inserting PCR
ampliﬁed or oligonucleotide annealed target sequences into a
dual-glo vector encoding Fireﬂy and Renilla luciferase (Promega).
All nucleic acid sequences are shown in Supplementary data
Table 1.
2.2. Cell culture and related assays
HEK 293 and Huh-7 cells were obtained from ATCC and cul-
tured in RPMI or Dulbecco’s modiﬁed Eagle’s (DMEM) media,
respectively, supplemented with 10% fetal bovine serum and anti-
biotics. An Evi1 expression vector was a kind gift of Dr. Hisamaru
Hirai (University of Tokyo, Tokyo, Japan). Antibodies used included
those to K-Ras, Evi1, GAPDH (Cell Signaling). Evi1 and control
siRNA were provided by SantaCruz Biotechnology. All transfections
were performed using Lipofectamine 2000, according to the
instructions of the manufacturer (Invitrogen). Cellular activity of
luciferase based reagents was quantiﬁed 48 h after cellular trans-
fection using the Dual-Glo™ (Promega) luciferase assay kit. Chro-
matin immunoprecipitation assays were performed according to
the manufacturer’s instructions using a ChIP assay kit (Upstate).
Brieﬂy, HEK 293 cells were transfected with an Evi1 expression
vector. After (48 h) transfection, cells were havested and DNA
was crosslinked to histone by adding 1% formaldehyde. Cell lysates
were prepared with SDS lysis buffer and subsequently sonicated to
shear DNA. Following immunoprecipitation of the diluted lysate
with the appropriate antibodies, the eluates were reverse cross-
linked and subjected to PCR with speciﬁc primers for the miRNA-
143 promoter region; 1% of lysate was used as the input control.
2.3. Human tissue
Rhode Island Hospital Human Subjects Committee approval
was gained to utilize primary tissue from a tumor bank of de-iden-
tiﬁed pathologist-reviewed samples obtained at surgical resection
and immediately snap frozen.
2.4. Northern blot
Total RNA (25 lg) was loaded on 15% acrylamide gel and trans-
ferred onto Hybond N+ membrane. The miRNA-143 probe (50-TGA
GAT GAA GCA CTG TAG CTC ACC TGT CTC-30) was labeled by using
Biotin RNA labeling kit (Roche). Hybridization was carried out at
42 C for 12 h and signal was detected by BrightStar BioDetect kit
(Ambion).
2.5. RT–PCR quantiﬁcation
Total RNA was extracted by TRIZOL and 1 lg RNA was used for
cDNA synthesis using MMLV reverse transcriptase (New England
Biolabs) with random primers. Primer sequences used are in the
Supplementary data Table. PCR analysis was performed by RT2
Real-Time™ SYBR Green PCR master mix (SuperArray) according
to the manufacturer’s protocol using the Eppendorf realplex2 Mas-
tercycler machine (Eppendorf). Results were normalized with re-
spect to beta-actin expression. TaqMan microRNA assays
(Applied Biosystems) that include RT primers and TaqMan probes
were used to quantify the expression of mature let7a and miR-
NA-143 in both tissue samples and cell lines. The mean Ct was
determined from triplicate PCR reactions. Gene expression was cal-
culated relative to actin expression, also quantiﬁed by independent
triplicate measurements.2.6. Directional motility and MTT assays
Directional motility was measured using the ATP Lumines-
cence-Based Motility-Invasion (ALMI) assay. Brieﬂy, serum-free
culture medium was placed in the bottoms of blind well chambers
(Neuro Probe, Gaithersburg, MD, USA) which were separated by
8-lm pore diameter polycarbonate ﬁlters from the upper cham-
bers. 100,000 viable Caco2 cells which had been transfected with
either a miRNA-143 expression vector or empty vector were
seeded into the upper chambers and cell migration was allowed
to proceed for 30 min at 37 C in a CO2 incubator. Cells collected
from either bottom, upper or undersurface of ﬁlters were quanti-
ﬁed using ATPLite reagent (Perkin–Elmer, Waltham, MA, USA).
The percentage of motile non-adherent cells in eight replicate as-
says was calculated and used for statistical analysis. The over all
survival of miRNA-143 or empty vector transfected cells was quan-
tiﬁed by MTT assay using Thiazolyl Blue Tetrazolium Bromide re-
agent with absorbance reading at 590 nm after addition of MTT
solvent (4 mM HCl, 0.1% Nondet P-40 (NP40) all in isopropanol).
2.7. Statistical analysis
Data analyses were conducted using non-parametric statistics
which do not require distributional assumptions of the data. Spe-
ciﬁcally, the Wilcoxon sign-rank test of the median was used to
compare the median of each pairwise difference to zero (no differ-
ence). This test is a non-parametric alternative to the paired t-test.
In addition, the Spearman’s rho (R, rank correlation coefﬁcient)
was used to measure the relationship between two variables.
Spearman’s rho is analogous to the Pearson product moment cor-
relation coefﬁcient but is calculated on ranked data, thus is robust
to extreme observations.
3. Results
3.1. The K-Ras 30-UTR harbors at least ﬁve miRNA-143 targets sites
The complexity of miRNA/target mRNA interaction derives from
emerging data that miRNA species may target not only the 30-UTR
but coding and promoter regions as well [7]. Within the 30-UTR,
several areas may harbor potential target sites. Indeed, previous re-
ports have identiﬁed and validated two miRNA-143 target sites in
the 30-UTR of K-Ras by using miRNA target algorithms such as
TargetScan, miRanda and PicTar [8]. Traditional luciferase based as-
saysinvolvingthesesitesrevealedreduction(30%)ofreporteractiv-
ity in the presence of miRNA-143. To determine whether additional
sites existed, we analyzed the K-Ras 30-UTR with rna22, a pattern
based miRNA target detection algorithm [7]. Rna22 identiﬁed three
additional targets for miRNA-143 in the 30-UTR of K-Ras (sites A–E,
Fig. 1a). We explored the validity of this bioinformatic forecast with
thehelpof luciferaseconstructsthatcontainedeachof the30-UTRtar-
get sites in turn. Individual reporter constructswere introduced into
HEK 293 cells along with a validatedmiRNA-143 expression or con-
trol plasmid. Luciferase levels were reduced by 20–70% (Fig. 1b).
We next probed the sequence speciﬁcity of this interaction by creat-
ing a series of miRNA-143 mutants harboring seed sequence
mismatches at 50 nucleotide positions 2–5 and 7. Compared towild-
type miRNA-143, all mutants harbored less activity against the
K-Ras 30-UTRwith themost severe reduction in function of mutants
with double or triplemismatches in the seed sequence (Fig. 1c).
3.2. Differential regulation of K-Ras in colon cancer by miRNA-let-7a
and miRNA-143
Regulation of K-Ras by members of the let-7 family has been






























EV miR-143 Mutant-1 Mutant-2 Mutant-3 Mutant-4
a c
b
Fig. 1. miRNA-143 targets K-Ras. (a) The 30-UTR of K-Ras harbors ﬁve potential sites (A–E) of sequence homology to the seed sequence of miRNA-143. Blue letters denote the
K-Ras mRNA target while red letters are used to denote miRNA-143 sequence. (:) Indicates GU pair (|) indicates normal bond. (b) K-Ras 30-UTR segments A–E were
incorporated into a dual luciferase reporter plasmid. All constructs were introduced into HEK 293 cells with miRNA-143 or an empty control vector (EV) and luminescence
was measured at 48 h. Compared to experiments involving EV, luciferase activity was repressed in all experiments involving the 30-UTR segments, albeit at variable levels. (c)
Point mutations were introduced into the seed sequence of miRNA-143 and four expression vectors were created (mutant 1–4). In the table, seed sequence is shown in bold
lettering; sequence changes for each mutant are underlined. Wildtype (WT), mutant and control (EV) plasmids were transfected into HEK 293 cells along with the dual
luciferase reporter plasmid and levels of luminescence were quantiﬁed at 48 h.
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sistent inverse relationship between let-7a levels and K-Ras
expression [3,9]. For example, in cancers of colon and breast,
the expression of let-7a is not as markedly decreased in cancer-
ous vs. adjacent normal tissue as with miRNA-143 [3,10]. To
determine whether any correlation existed between the expres-
sion of K-Ras, let-7a and miRNA-143 in colon cancer, we ﬁrst
quantiﬁed mature miRNA levels by real time PCR and northernblot in twenty human samples of cancerous and adjacent normal
colonic tissue. Indeed, levels of miRNA-143 were reduced an aver-
age of fourfold in neoplastic tissue compared to surrounding nor-
mal tissue (P = 0.001); however, the levels of let-7a showed no
statistically signiﬁcant difference (P = 0.263) (Fig. 2a and b). As
expected, expression of K-Ras protein was inversely related to
miRNA-143 expression in the colon cancer samples studied by
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Fig. 2. Differential expression of miRNA-143, let-7a and K-Ras in colon cancer. (a)
Real-time RT-PCR was used to quantify levels of mature miRNA-143 and let-7a in
20 samples of human colon cancer in both frank cancerous tissue and surrounding
normal adjacent tissue (NAT). Patterns of expression are presented as fold
comparisons between cancerous and NAT for each miRNA (miRNA-143: dark blue
bars and let-7a: light blue bars). Data from 18 samples are presented; two outliers
(cases # 4 and #13) with a >50 fold difference in miRNA-143 expression are omitted
for graphical clarity. We observed a statistically signiﬁcant under-expression of
miRNA-143 in cancerous tissue vs. NAT (P = 0.001). No such relationship was found
for let-7a (P = 0.263). (b) In agreement with real time RT-PCR data for mature
miRNA expression level, northern blots indicated a decreased level of miRNA-143 in
cancerous tissue compared to NAT. No such difference was observed for let-7a in
the samples studied. A strong inverse relationship was observed between levels of
miRNA-143 and K-Ras, the latter quantiﬁed by western blot. GAPDH protein levels
served as a loading control for western blot.
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Why are levels of mature miRNA-143 reduced in colonic neo-
plastic tissue compared to paired normal tissue? Antecedent steps
in the biogenesis of mature miRNA involve their transcription as
long primary (pri-) molecules and subsequent cleavage into short-
er precursor (pre-) molecules by the protein Drosha in the nucleus.
We quantiﬁed levels of pre-miRNA-143 by real time PCR and found
that levels were reduced by 50% in neoplastic tissue compared to
normal tissue (P = 0.02). There was a statistically signiﬁcant corre-
lation between pri-miRNA-143 and pre-miRNA-143 values
(R = 0.72; P = 0.001) as there was between precursor forms and
mature miRNA (R = 0.51; P = 0.02). These ﬁndings are in agreement
with earlier reports of miRNA-143 kinetics, albeit in murine sys-
tems, that demonstrated matched expression of precursor and ma-
ture miRNA-143 transcripts [11]. Thus, altered transcription of the
miRNA-143 gene emerged as one potential explanation for reduced
mature miRNA-143 accumulation in cancerous tissue.
To identify potential regulators of miRNA-143 transcription we
utilized a bioinformatic promoter mapping program. Our overallapproach was guided by recent work demonstrating that 60% of
miRNAs have transcription factor (TF) binding sites within 1 kb
of the start of the pre-miRNA sequence [12]. Our analysis identiﬁed
four putative binding sites for the ecotropic viral integration site 1
(Evi1) protein in a 2kB region upstream of the miRNA-143 precur-
sor with three of the sites located within 1 kb of the precursor
(Fig. 3a). The Evi1 gene encodes a zinc ﬁnger protein that impacts
normal development as well as cellular proliferation, development
and apoptosis [13,14]. To experimentally verify Evi1/miRNA-143
gene locus interaction we performed chromatin immunoprecipita-
tion (ChIP) assays. HEK 293 cells were transfected with an Evi1
expression vector (pEvi1) and chromatin fragments were immuno-
precipitated with an antibody to Evi1. Speciﬁc primers were then
used to amplify DNA fragments from the immunoprecipitates.
The promoter region of the human promyelocytic leukemia zinc
ﬁnger (PLZF) was used as a positive control given previous demon-
stration of its direct binding to and transcriptional control of the
Evi1 gene [15]. A control DNA fragment harboring no predicted
binding sites served as a negative control. As seen in Fig. 3b, the
miRNA-143 and PLZF promoter regions but not the control frag-
ment could be immunoprecipitated by antibodies to Evi1 thereby
assigning binding speciﬁcity to Evi1. Next, we generated a series
of luciferase based reporter vectors, each harboring a more trun-
cated region of the miRNA-143 promoter region. These vectors
were transfected into HEK 293 cells with an Evi1 expression plas-
mid (pEvi1). Normalized values reﬂected a decrease in reporter
activity with increasing promoter length; constructs containing
all four Evi1 binding sites were the most inhibitory to luciferase
expression (Fig. 3c). Finally, dose dependency of the Evi1 effect
was demonstrated by transfecting increasing amounts of pEvi1
with the promoter construct harboring all four binding sites. As
seen in Supplementary Fig. 1, increasing the amount of transfected
pEvi1 was associated with corresponding decreased promoter
activity.
3.4. The Evi1, miRNA-143 and K-Ras axis in human cancer
Further support for the role of Evi1 in controlling miRNA-143
transcription derived from experiments involving cell lines with
different levels of miRNA-143/Evi1 expression. First, we observed
an inverse relationship between levels of Evi1 and pri-miRNA-
143 in HCT116, HT29 and Caco2 cells (e.g., Caco2/HT29miRNA-143
low/Evi1 high vs. HCT116miRNA-143 high/Evi1 low) (Fig. 4a). As expected,
levels of K-Ras were correlated to levels of Evi1 and miRNA-143
(Fig. 4b). To stringently test the causal nature of this relationship,
we manipulated Evi1 levels in HCT116 and Caco2 cell lines. Ectopic
expression of Evi1 in HCT116 cells led to 50% reduction (P < 0.05)
in pri-miRNA-143 levels (Fig. 4c). In contrast, treatment of Caco2
cells with arsenic trioxide, a known and potent inhibitor of Evi1
as well as siRNA targeting Evi1, led to a 2-fold statistically signif-
icant increase in miRNA-143 levels and a concomitant decrease in
K-RAS (Fig. 4d and e). The siRNAs were validated prior to use and
reduced Evi1 mRNA levels by 60% (data not shown). The rela-
tively low levels of miRNA-143 in Caco2 cells allowed us to gauge
the functional effect of ectopic miRNA-143 expression. We com-
pared cellular motility and proliferation in cells that had been
transfected with either an empty vector or a miRNA-143 expres-
sion cassette. As seen in Fig. 4e and f, ectopic miRNA-143 expres-
sion decreased proliferative capacity and motility, respectively.
We next proﬁled Evi1 protein expression in cancerous and nor-
mal colonic tissue. As seen in Fig. 5, cancerous tissue was associ-
ated with an increased expression of Evi1 protein in samples
studied by western blot. When the analysis was extended to the
RNA level in twenty further samples, we found that 75% of samples
(15/20) had an average 4-fold increase in Evi1 RNA levels in can-
cerous vs. normal colonic tissue. A similar level of increase has
Chr 5 -1494 -1367 -908 -432 -1 Pre-miR-143
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Fig. 3. Evi1 is a transcriptional suppressor of miRNA-143. (a) Schematic diagram of miRNA-143 genomic locus on chromosome 5. Four putative Evi1 binding sites exist in a
2kb region upstream of the start of pre-miRNA-143, denoted by black boxes. Consensus binding sequence is annotated below each box. Arrows ‘a’ and ‘b’ correspond to
primer locations for ampliﬁcation of recovered DNA for use in the ChIP assay. (b) Chromatin was immunoprecipitated with anti-Evi1 antibody and oligonucleotides ‘a’ and ‘b’
were used to PCR amplify the recovered DNA. Control ampliﬁcations were carried out using primers speciﬁc for the promoter region of the PLZF gene, a known transcriptional
target of Evi1. A gene with no known regulation by Evi1 (GAPDH) served as a negative control. (c) We generated a series of miRNA-143 promoter region luciferase reporter
constructs containing 0 (TF1), 2 (TF2) or all 4 (TF3) putative Evi1 binding sites. Lower panel: The constructs were transfected into HEK 293 cells and luminescence was
measured at 48 h. Data are shown as average reduction (±S.D.) in promoter activity relative to the basal endogenous pri-miRNA-143 promoter activity (TF1). Promoter activity
was reduced by 80% in experiments involving TF3.
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with decreased levels of miRNA-143 [16,17]. Thus, as with our
in vitro experiments, our data involving primary cancerous and
normal tissue pointed to a pathway in which Evi1 suppresses miR-
NA-143 gene transcription which in turn leads to elevated levels of
K-Ras in colon cancer.
4. Discussion
Small RNA species such as miRNA are increasingly being recog-
nized as inﬂuencing a myriad processes relevant to health and dis-
ease. In the setting of malignancy, numerous reports have used
array technology to obtain quantitative information on miRNA
expression patterns and a set of ‘‘oncomirs’’ has been identiﬁed.While much work has been done in establishing bonaﬁde targets
of disease related miRNA, relatively less is known about the tran-
scriptional networks that mediate miRNA gene expression. Here,
we provide evidence that the miRNA-143 locus in under the tran-
scriptional repression of Evi1. Exploitation of pro-survival signaling
pathways is a hallmark of the cancer cell [18]. Previous work has
demonstrated that Evi1 functions as a survival gene in intestinal
cells and mediates resistance to apoptotic stimuli by inhibiting
components of TGFb signaling [19]. More recently, Evi1 expression
has been associated with DNA methylation and silencing of the
miRNA-124 locus [20]. Our work broadens the role of Evi1 in colo-
nic carcinogenesis to include components of the miRNA pathway
affecting cellular levels of the K-Ras oncogene. While our experi-
























































Fig. 4. We proﬁled levels of pri-miRNA-143 and Evi1 in three colon cancer cell lines (CaCO2, HT29 and HCT116). (a) We observed an inverse relationship between levels of
Evi1 and pri-miRNA-143, as measured by real time PCR. (b) Western blotting revealed a direct relationship between levels of Evi1 and K-Ras in HCT116 and CaCO2 cells. Beta
actin and GAPDH were used to normalize RNA and protein input for RT-PCR and western blot, respectively. (c) Overexpression of Evi1 in HCT116 cells by transient
transfection of an expression plasmid led to a 50% reduction in pri-miRNA-143 levels. In contrast, depletion of Evi1 in CaCO2 cells by speciﬁc siRNA or arsenic trioxide (ATO)
both for 24 h led to a 2-fold increase in pri-miRNA-143 levels (d). Western blot of cells treated with either anti-Evi1 siRNA (48 h) or ATO (24 h) revealed a decrease in levels
of Evi1 and K-Ras proteins in CaCO2 cells (e). We measured the effect of miRNA-143 over expression in Caco2 cells by MTT assay (f) and motility assay (g). Over expression
was associated with decreased proliferation and motility, respectively.
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Fig. 5. Multiple isoforms of EVi1 exist due to alternative splicing and usage of 50-
ends. Intergenic splicing leads to the formation of a fusion protein with MDS1.
Western blotting of colonic tissue revealed over expression of Evi1, MDS1/Evi1 and
a truncated version of Evi1 (DEvi1) in tumor tissue (T) compared to surrounding
normal tissue (N). Similar expression patterns of MDS1/Evi1 and Evi1 have been
recently described in ovarian cancer tissue and cell lines [17].
J.-S. Gao et al. / FEBS Letters 585 (2011) 693–699 699it would be worthwhile to determine whether this axis is opera-
tional in other cancers associated with miRNA-143 under expres-
sion (e.g., ovarian, esophageal, bladder and B-cell cancer). Lastly,
our ﬁndings suggest that pharmacologic targeting of Evi1 may lead
to miRNA-143 up-regulation which may offer therapeutic beneﬁt
in colon cancer.
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